Austin, Texas, USA, April 21, 2026

In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for next-generation hydrocortisone acetate (ngHCA), a novel rectal suppository designed for the treatment of ulcerative colitis (UC) of the rectum. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of October 2026, marking a critical step toward potential approval. Backed by positive results from the Phase 3 CESSA clinical trial, the therapy demonstrated statistically significant clinical remission rates, positioning ngHCA as a promising new option for patients suffering from this chronic and often debilitating inflammatory condition.

ngHCA Addresses Unmet Needs in UC Treatment

Ulcerative colitis is a chronic autoimmune gastrointestinal disease affecting approximately 1.3 million patients in the United States, characterized by inflammation of the colon and rectum, leading to symptoms such as rectal bleeding, severe diarrhea, abdominal pain, and urgency. Despite available therapies, many patients continue to experience frequent disease flares and inadequate symptom control, particularly in cases involving rectal inflammation.

Cristcot’s ngHCA suppository is designed to directly target inflammation at the site of disease, offering localized treatment with minimal systemic exposure. If approved, ngHCA would become the first and only FDA-approved hydrocortisone acetate suppository, addressing a longstanding gap in treatment options for rectal UC. The therapy leverages a novel formulation and delivery system, enhancing drug bioavailability while improving patient compliance compared to traditional treatments.

Innovative Delivery System Enhances Therapeutic Impact

Advertisement

cGxPJobs Banner

A key differentiator of ngHCA is its use of Cristcot’s patented Sephure® suppository applicator, which enables precise, patient-friendly administration of the therapy. This advanced delivery mechanism ensures rapid and sustained release of hydrocortisone acetate, optimizing therapeutic effectiveness while reducing systemic side effects commonly associated with corticosteroids. Rectally administered therapies are particularly important in UC management, as they allow for direct drug delivery to inflamed tissues, improving treatment outcomes.

The small-volume suppository design further enhances ease of use, addressing adherence challenges that often limit the effectiveness of existing therapies. This combination of innovative drug formulation and delivery technology positions ngHCA as a potentially transformative solution in the management of inflammatory bowel disease (IBD).

Regulatory Progress and Commercial Outlook

The acceptance of the NDA under the 505(b)(2) regulatory pathway reflects the FDA’s recognition of ngHCA’s potential to address a significant unmet medical need. Cristcot has already initiated commercial launch readiness planning for Q4 2026, signaling confidence in the therapy’s market potential. The company’s broader pipeline includes investigational treatments for acute pancreatitis, hemorrhoid disease, and other inflammatory gastrointestinal conditions, underscoring its commitment to advancing patient-centric solutions in GI disorders.

With ulcerative colitis often requiring long-term disease management, the introduction of a targeted, effective, and well-tolerated therapy like ngHCA could significantly improve patient quality of life and clinical outcomes.

Overall, Cristcot’s NDA acceptance marks a pivotal moment in the evolution of ulcerative colitis treatment, offering hope for improved management of a disease that continues to impose a heavy burden on patients and healthcare systems alike. By combining clinical efficacy, innovative delivery, and regulatory momentum, ngHCA stands poised to redefine the standard of care for rectal UC and reinforce Cristcot’s position in the gastrointestinal therapeutics landscape.

Source: Cristcot press release